CTSC:TTIC.101910
From NAMIC Wiki
Revision as of 19:16, 25 October 2010 by Valerie.humblet (talk | contribs) (→Harvard Translational Imaging Consortium Meeting Minutes October 12, 2010)
Home < CTSC:TTIC.101910
Back to Collaboration:Harvard_CTSC
Agenda
- Consultations update
- Imaging in oncology (BIDMC, Oct 13) and Neuroimaging (MGH Oct 18)
- RSNA practice talk (Thursday November 18, 12-2 pm, Armenise Bllg, amphitheater D).
- New Harvard Catalyst website
- Multicenter trials subgroup
Harvard Translational Imaging Consortium Meeting Minutes October 19, 2010
In attendance:
- Valerie Humblet
- Randy Gollub
- Bob Lenkinski
- Ivan Pedrosa
- Annick Van den Abbeele
- Simon Warfield
- Gordon Harris
- Jeff Yap
- Laura Alice
- Clare Tempany
- Ron Kikinis
1. Consultations update
- This week we had 2 new requests for consultation, both for Randy: fMRI in spine pain and Identifying the Neural Correlates of the Owner-Dog Bond Using Functional Magnetic Resonance Imaging (fMRI).
2. Imaging in oncology (BIDMC, Oct 13) and Neuroimaging (MGH Oct 18)
- For both sessions, the attendance was about 30-50 %. The ration speaker/attending is not very good. We might think of other formats for our next sessions. According to attendees' feedback, it is hard for researchers and even more for clinicians to commit for a whole afternoon.
- One suggestion that generated a lot of interest is having series during lunch time with guest presenters from the different hospitals. Below are 2 propositions:
- FMRI: 1 introductory lecture + 1 lecture on biomarkers in fMRI (both at HMS) then a series of lectures that are site specifics (MGH, BIDMC, CHB, BWH, MIT, McLean etc)
- US: 1 introductory lecture + 1 lecture on biomarkers in US (both at HMS) then a couple lectures on use of US in clinical trial as well as a lecture on the basics steps to include US in studies (IND preparation etc)
RSNA proposal:
The objectives of the course are:
(a) to present current directions of quantitative imaging as a biomarker in clinical trials.
(b) to review the steps involved in the integration of an imaging biomarker into a multi-center clinical trial (protocol development, scanner qualification, standardization of image acquisition, data management, quality assurance, central review and analysis, validation, dissemination)
(c) to discuss examples of quantitative imaging best practice in PET/CT, MRI and pediatric imaging
